University of Maryland (UM) Ventures announced today that the University of Maryland, Baltimore (UMB) has granted worldwide, exclusive licensing rights for a new vaccine technology to Serenta Biotechnology, LLC, a Gaithersburg, MD-based startup. The license is based on technology co-owned by UMB and Northern Arizona University and is the basis for a multivalent vaccine against infections caused by Staphylococcus aureus, a bacterial strain often resistant to antibiotics.
{iframe}http://www.prnewswire.com/news-releases/university-of-maryland-baltimore-and-serenta-team-up-to-fight-staph-infections-300465036.html{/iframe}